Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia

Valentina Serafin, Giorgia Capuzzo, Gloria Milani, Sonia Anna Minuzzo, Marica Pinazza, Roberta Bortolozzi, Silvia Bresolin, Elena Porcù, Chiara Frasson, Stefano Indraccolo, Giuseppe Basso, Benedetta Accordi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pediatric T-Acute lymphoblastic leukemia (T-ALL) patients often display resistance to glucocorticoid (GC) treatment. These patients, classified as prednisone poor responders (PPR), have poorer outcome than do the other pediatric T-ALL patients receiving a highrisk adapted therapy. Because glucocorticoids are administered to ALL patients during all the different phases of therapy, GC resistance represents an important challenge to improving the outcome for these patients. Mechanisms underlying resistance are not yet fully unraveled; thus our research focused on the identification of deregulated signaling pathways to point out new targeted approaches. We first identified, by reverse-phase protein arrays, the lymphocyte cell-specific protein-Tyrosine kinase (LCK) as aberrantly activated in PPR patients. We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations. This was confirmed by specificLCKgene silencing and ex vivo combined treatment of cells fromPPRpatient-derived xenografts. Moreover, we observed that LCK hyperactivation in PPR patients upregulates the calcineurin/nuclear factor of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression. GC-sensitive cells cultured with IL-4 display an increased resistance to dexamethasone, whereas the inhibition of IL-4 signaling could increase GC-induced apoptosis in resistant cells. Treatment with dexamethasone and dasatinib also impaired engraftment of leukemia cells in vivo. Our results suggest a quickly actionable approach to supporting conventional therapies and overcoming GC resistance in pediatric T-ALL patients.

Original languageEnglish
Pages (from-to)2750-2761
Number of pages12
JournalBlood
Volume130
Issue number25
DOIs
Publication statusPublished - Dec 21 2017

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
T-cells
Glucocorticoids
Prednisone
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interleukin-4
Dexamethasone
Therapeutics
NFATC Transcription Factors
Cell signaling
Protein Array Analysis
Lymphocytes
Glucocorticoid Receptor Deficiency
Calcineurin
Cell death
Heterografts
Protein-Tyrosine Kinases
Cultured Cells
Leukemia

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Serafin, V., Capuzzo, G., Milani, G., Minuzzo, S. A., Pinazza, M., Bortolozzi, R., ... Accordi, B. (2017). Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood, 130(25), 2750-2761. https://doi.org/10.1182/blood-2017-05-784603

Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. / Serafin, Valentina; Capuzzo, Giorgia; Milani, Gloria; Minuzzo, Sonia Anna; Pinazza, Marica; Bortolozzi, Roberta; Bresolin, Silvia; Porcù, Elena; Frasson, Chiara; Indraccolo, Stefano; Basso, Giuseppe; Accordi, Benedetta.

In: Blood, Vol. 130, No. 25, 21.12.2017, p. 2750-2761.

Research output: Contribution to journalArticle

Serafin, V, Capuzzo, G, Milani, G, Minuzzo, SA, Pinazza, M, Bortolozzi, R, Bresolin, S, Porcù, E, Frasson, C, Indraccolo, S, Basso, G & Accordi, B 2017, 'Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia', Blood, vol. 130, no. 25, pp. 2750-2761. https://doi.org/10.1182/blood-2017-05-784603
Serafin, Valentina ; Capuzzo, Giorgia ; Milani, Gloria ; Minuzzo, Sonia Anna ; Pinazza, Marica ; Bortolozzi, Roberta ; Bresolin, Silvia ; Porcù, Elena ; Frasson, Chiara ; Indraccolo, Stefano ; Basso, Giuseppe ; Accordi, Benedetta. / Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. In: Blood. 2017 ; Vol. 130, No. 25. pp. 2750-2761.
@article{5d84e6ec04b54f5a9e7a4f5718fded6b,
title = "Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia",
abstract = "Pediatric T-Acute lymphoblastic leukemia (T-ALL) patients often display resistance to glucocorticoid (GC) treatment. These patients, classified as prednisone poor responders (PPR), have poorer outcome than do the other pediatric T-ALL patients receiving a highrisk adapted therapy. Because glucocorticoids are administered to ALL patients during all the different phases of therapy, GC resistance represents an important challenge to improving the outcome for these patients. Mechanisms underlying resistance are not yet fully unraveled; thus our research focused on the identification of deregulated signaling pathways to point out new targeted approaches. We first identified, by reverse-phase protein arrays, the lymphocyte cell-specific protein-Tyrosine kinase (LCK) as aberrantly activated in PPR patients. We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations. This was confirmed by specificLCKgene silencing and ex vivo combined treatment of cells fromPPRpatient-derived xenografts. Moreover, we observed that LCK hyperactivation in PPR patients upregulates the calcineurin/nuclear factor of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression. GC-sensitive cells cultured with IL-4 display an increased resistance to dexamethasone, whereas the inhibition of IL-4 signaling could increase GC-induced apoptosis in resistant cells. Treatment with dexamethasone and dasatinib also impaired engraftment of leukemia cells in vivo. Our results suggest a quickly actionable approach to supporting conventional therapies and overcoming GC resistance in pediatric T-ALL patients.",
author = "Valentina Serafin and Giorgia Capuzzo and Gloria Milani and Minuzzo, {Sonia Anna} and Marica Pinazza and Roberta Bortolozzi and Silvia Bresolin and Elena Porc{\`u} and Chiara Frasson and Stefano Indraccolo and Giuseppe Basso and Benedetta Accordi",
year = "2017",
month = "12",
day = "21",
doi = "10.1182/blood-2017-05-784603",
language = "English",
volume = "130",
pages = "2750--2761",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia

AU - Serafin, Valentina

AU - Capuzzo, Giorgia

AU - Milani, Gloria

AU - Minuzzo, Sonia Anna

AU - Pinazza, Marica

AU - Bortolozzi, Roberta

AU - Bresolin, Silvia

AU - Porcù, Elena

AU - Frasson, Chiara

AU - Indraccolo, Stefano

AU - Basso, Giuseppe

AU - Accordi, Benedetta

PY - 2017/12/21

Y1 - 2017/12/21

N2 - Pediatric T-Acute lymphoblastic leukemia (T-ALL) patients often display resistance to glucocorticoid (GC) treatment. These patients, classified as prednisone poor responders (PPR), have poorer outcome than do the other pediatric T-ALL patients receiving a highrisk adapted therapy. Because glucocorticoids are administered to ALL patients during all the different phases of therapy, GC resistance represents an important challenge to improving the outcome for these patients. Mechanisms underlying resistance are not yet fully unraveled; thus our research focused on the identification of deregulated signaling pathways to point out new targeted approaches. We first identified, by reverse-phase protein arrays, the lymphocyte cell-specific protein-Tyrosine kinase (LCK) as aberrantly activated in PPR patients. We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations. This was confirmed by specificLCKgene silencing and ex vivo combined treatment of cells fromPPRpatient-derived xenografts. Moreover, we observed that LCK hyperactivation in PPR patients upregulates the calcineurin/nuclear factor of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression. GC-sensitive cells cultured with IL-4 display an increased resistance to dexamethasone, whereas the inhibition of IL-4 signaling could increase GC-induced apoptosis in resistant cells. Treatment with dexamethasone and dasatinib also impaired engraftment of leukemia cells in vivo. Our results suggest a quickly actionable approach to supporting conventional therapies and overcoming GC resistance in pediatric T-ALL patients.

AB - Pediatric T-Acute lymphoblastic leukemia (T-ALL) patients often display resistance to glucocorticoid (GC) treatment. These patients, classified as prednisone poor responders (PPR), have poorer outcome than do the other pediatric T-ALL patients receiving a highrisk adapted therapy. Because glucocorticoids are administered to ALL patients during all the different phases of therapy, GC resistance represents an important challenge to improving the outcome for these patients. Mechanisms underlying resistance are not yet fully unraveled; thus our research focused on the identification of deregulated signaling pathways to point out new targeted approaches. We first identified, by reverse-phase protein arrays, the lymphocyte cell-specific protein-Tyrosine kinase (LCK) as aberrantly activated in PPR patients. We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations. This was confirmed by specificLCKgene silencing and ex vivo combined treatment of cells fromPPRpatient-derived xenografts. Moreover, we observed that LCK hyperactivation in PPR patients upregulates the calcineurin/nuclear factor of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression. GC-sensitive cells cultured with IL-4 display an increased resistance to dexamethasone, whereas the inhibition of IL-4 signaling could increase GC-induced apoptosis in resistant cells. Treatment with dexamethasone and dasatinib also impaired engraftment of leukemia cells in vivo. Our results suggest a quickly actionable approach to supporting conventional therapies and overcoming GC resistance in pediatric T-ALL patients.

UR - http://www.scopus.com/inward/record.url?scp=85039149253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039149253&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-05-784603

DO - 10.1182/blood-2017-05-784603

M3 - Article

VL - 130

SP - 2750

EP - 2761

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -